The global research-based pharmaceutical industry lies increasingly between the "rock" of empty pipelines and the "hard place" of cost containment and more aggressive generic competition. In this environment it is essential to exploit the whole spectrum of available lifecycle management (LCM) options to maximize the performance of existing brand assets...
More...
More...